Lihan Zhou
周砺寒
Lihan Zhou is a co-founder and CEO of Mirxes (觅瑞/MiRXES), a Singapore-based company developing early-stage cancer screening kits using microRNA (miRNA) technology . The company was profiled by Gaorong Ventures in late 2021 as part of its "Future" series on biotech innovation . Beyond this, elsewhere's corpus does not cover Zhou's background, education, or prior career in depth.
AI-generated — may contain errors, please verify.
Coverage
Congratulations to Mirxes on its successful listing on the Hong Kong Stock Exchange's Main Board — Gaorong Ventures was its earliest institutional investor.
A leading provider of molecular cancer screening products and services.
高榕创投·From Nobel Discovery to Clinical Application: Mirxes Is Transforming Cancer Early Screening with miRNA Technology | Gaorong Ventures
Focused on miRNA technology development, pioneering early cancer screening worldwide.
高榕创投·Mirxes Completes $50 Million Series D to Accelerate Cancer Early-Screening Pipeline R&D and Commercialization
Focused on innovative blood-based early screening products and services for cancer.
高榕创投·"Tiny but Mighty" miRNA: How Cancer Can Be Caught at Its Earliest Stage | Gaorong Ventures "Future"
By applying microRNA to early cancer screening, we can transform cancer from a terminal illness into a chronic disease that can be intercepted at an early stage.
高榕创投·Mirxes Completes $87 Million Series C Round to Develop Early Cancer Screening Products Based on Leading miRNA Technology
Focused on microRNA technology, dedicated to early disease diagnosis.
高榕创投·
